AstraZaneca

SERENA 4

NCT04711252

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

Status:

Opening soon

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced /Metastatic

Disease Stage

Target.png

Biomarker(s)

ER+, HER2-

Investigational

Product

AZD9833

Treatment Arms

o AZD9833 + palbociclib

o Anastrozole + palbociclib